每经AI快讯，10月30日，港股生物科技板块集体走弱，荃信生物-B、维立志博-B跌超10%，荣昌生物、 君实生物、药明生物纷纷下挫。 ...

Group 1 - The Hang Seng Index closed down 0.33% after a weak performance throughout the day, with the Hang Seng Tech Index experiencing the largest decline [1] - The Hang Seng Tech Index fell by 1.44%, with notable declines in stocks such as SMIC down 3.26%, while NetEase rose by 2.35% [3] - Healthcare stocks continued to weaken, closing down 1.37%, with WuXi AppTec dropping 2% and other companies like Innovent Biologics and 3SBio also experiencing declines [3] Group 2 - Bank stocks rebounded after hitting a low, closing up 1.2%, with HSBC rising by 4.41% and Standard Chartered increasing by 3.73% [3] - Other banks such as Bank of China Hong Kong, Agricultural Bank of China, and Postal Savings Bank also saw gains of over 1% [3]

Core Insights - The best-performing fund managed by Zhao Zongting is the Huaxia National Index Semiconductor Chip ETF (159995), which achieved a quarterly net value increase of 53.81% as of Q3 2025 [1][2]. Fund Performance Summary - Zhao Zongting manages a total of 9 funds, with the following notable performances: - Huaxia National Index Semiconductor Chip ETF: 286.01 billion CNY, annualized return of 11.22%, and a quarterly increase of 53.81% [2]. - Huaxia CSI 300 ETF: 280.61 billion CNY, annualized return of 7.35%, and a quarterly increase of 19.04% [2]. - Huaxia Nasdaq 100 ETF (QDII): 111.02 billion CNY, annualized return of 17.40%, and a quarterly increase of 8.08% [2]. - Huaxia S&P 500 ETF (QDII): 33.65 billion CNY, annualized return of 20.10%, and a quarterly increase of 7.16% [2]. Stock Trading Cases - Notable stock trading cases managed by Zhao Zongting include: - Wuliangye (000858): Purchased in Q3 2017 and sold in Q4 2022, with an estimated return of 194.34% and a company profit growth of 175.90% during the holding period [5]. - Xingyuan Material (300568): Purchased in Q2 2021 and sold in Q3 2021, with an estimated return of 97.42% and a company profit growth of 133.49% during the holding period [5]. - Zijin Mining (601899): Purchased in Q4 2023 and sold in Q3 2024, with an estimated return of -86.51% despite a company profit growth of 51.76% during the holding period [5]. Fund Manager's Performance - Zhao Zongting's cumulative return as the manager of Huaxia CSI 300 ETF Link A (000051) is 56.2%, with an average annualized return of 5.36% [2]. - The fund had 75 adjustments in heavy stocks, with a success rate of 58.67% [2].

恒生指数开盘后直线拉升，随后维持在中轴上方窄幅盘整，截至午盘上涨1.02%。互联网涨幅居前，科 技、大消费、医疗、银行等紧随其后。 消费大幅高开后震荡盘整，截止午盘上涨1.4%。其中药明生物大涨3.31%，古茗上涨2.82%，申洲国际 上涨2.82%，阿里健康、百威亚大、创科实业等多股涨幅均在2%上方。 医疗高开低走，截至目前上涨0.9%。其中阿里健康大涨2.87%，药明生物上涨2.76%，百济神州上涨 1.86%，三生药业、中国生物制药、信达生物、京东健康等均有不错表现。 内容只是个人观点，仅供参考，不作为投资依据！欢迎关注交流，互相学习、共同探讨！ 互联网大幅高开后维持在高位盘整，截至午盘上涨2.27%。其中百度集团大涨5.6%，阿里巴巴上涨 3.21%，京东集团、腾讯控股、商汤等多股涨幅均值3%上方。 ...

Core Viewpoint - The A-share and Hong Kong stock markets experienced a collective rise, with the CXO sector leading the pharmaceutical industry, indicating a positive trend in the market [1] Group 1: Market Performance - Key indices in the A-share and Hong Kong markets surged, with the CXO sector leading the pharmaceutical segment [1] - The Hang Seng Biotechnology Index showed fluctuations but ultimately rose, with companies like WuXi AppTec, WuXi Biologics, and WuXi PharmaTech seeing significant gains [1] - The Hang Seng Pharmaceutical ETF (159892) increased by over 1% during intraday trading [1] Group 2: Company Financials - WuXi AppTec's Q3 report revealed a shareholder profit of 11.802 billion yuan for the first three fiscal quarters, marking an 80.65% year-on-year increase [1] - The total revenue for WuXi AppTec reached 32.857 billion yuan, reflecting an 18.61% year-on-year growth [1] Group 3: Industry Outlook - Huafu Securities noted that both macro (overseas investment and financing) and micro (performance of overseas CXO companies) perspectives indicate that the overseas CXO industry is entering a phase of accelerated recovery [1] - There is a need to pay attention to the allocation opportunities in domestic and foreign demand-driven CXO companies [1]

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" [2] Core Views - The pharmaceutical industry is showing signs of marginal improvement, with Q3 performance expected to exceed expectations in high-growth areas [4][14] - The report suggests focusing on companies with strong Q3 performance, particularly in the CXO and life sciences upstream supply chain, medical device recovery, and innovative drugs [4][14] Summary by Sections Q3 Performance Highlights - Q3 performance is expected to be outstanding or exceed expectations, with recommendations to focus on companies such as Baipusais, Haoyuan Pharmaceutical, and Bid Pharmaceutical in the upstream research chain [4][14] - Medical devices are stabilizing or reversing in Q3, with suggested companies including Kefu Medical, Haitai New Light, and Maipu Medical [4][14] - Some traditional Chinese medicine companies are beginning to stabilize and are expected to benefit from the basic drug catalog catalyst, with recommendations for companies like Fangsheng Pharmaceutical and Kang Enbei [4][14] - API companies are stabilizing at the bottom, with CDMO business growth accelerating, recommending companies like Puluo Pharmaceutical and Tonghe Pharmaceutical [4][14] - The upstream pharmaceutical equipment is starting to stabilize, with recommendations for companies such as Sensong International and Chutian Technology [4][14] CXO and Life Sciences Upstream Supply Chain - Recommendations for globally influential CXO leading companies include WuXi AppTec, WuXi Biologics, and Kanglong Chemical [4][18] - For domestic clinical CRO leaders, companies like Tigermed and Pruvis are suggested [4][18] - Resource-based CXOs represented by safety evaluation and model animals include Zhaoyan New Drug and MediWest [4][18] - In the life sciences upstream supply chain, companies such as Baipusais and Haoyuan Pharmaceutical are recommended [4][18] High-end Medical Devices - The recovery of in-hospital procurement is driving business growth, with recommendations for companies like United Imaging and Kailing Medical [4][6][18] - The demand for consumer medical devices is gradually recovering, with suggested companies including Kefu Medical and Sanofi [4][6][18] - Companies benefiting from overseas orders recovery include Meihua Medical and Haitai New Light [4][6][18] - The market penetration rate of high-end medical device consumables continues to rise, with recommendations for companies like Maipu Medical and Xinhu Medical [4][6][18] Innovative Drugs - Focus on companies with scientific breakthroughs and forward-looking market space, including Innovent Biologics, Hengrui Medicine, and Junshi Biosciences [4][6][18] Market Performance - The pharmaceutical sector's return was 0.58% last week, ranking 25th among 31 first-level sub-industry indices [5][15] - The pharmaceutical industry index's current PE (TTM) is 30.35 times, which is relatively low compared to its historical average [19][24]

Core Viewpoint - The Hong Kong Innovative Drug 50 ETF (513780) has shown significant growth, with a 44.49% increase over the past six months, indicating strong performance in the innovative pharmaceutical sector [1][2] Group 1: ETF Performance - As of October 27, 2025, the Hong Kong Innovative Drug 50 ETF rose by 1.16%, reaching a peak increase of over 2% during the trading session [1] - The ETF ranks first among similar index funds in terms of growth, reflecting robust investor interest in innovative pharmaceuticals [1] Group 2: Company Earnings - WuXi AppTec reported a revenue of 32.857 billion yuan for the first three quarters of 2025, marking an 18.61% year-on-year increase, with a net profit of 12.076 billion yuan, up 84.84% [1] - In Q3 2025, the company achieved a revenue of 12.057 billion yuan, a 15.26% increase year-on-year, and a net profit of 3.515 billion yuan, reflecting a 53.27% growth [1] Group 3: Market Trends and Insights - Everbright Securities noted that the Federal Reserve has initiated a rate-cutting cycle, which is favorable for the innovative pharmaceutical sector, particularly for innovative drugs and devices [1] - The current investment focus in the pharmaceutical industry should emphasize clinical value, addressing patient needs, with both domestic and international policies providing higher premiums for clinical value [1] - The reduction in interest rates is expected to improve the financing environment for pharmaceutical companies, particularly benefiting biotech firms and increasing demand for CXO services, positively impacting new orders and performance growth [1] Group 4: Industry Dynamics - The innovative drug market is transitioning from a broad rally to a focus on "quality factors," where only leading innovative drugs with strong clinical data and commercialization capabilities will achieve financial success [2] - The Hong Kong Innovative Drug 50 ETF tracks the CSI Hong Kong Stock Connect Innovative Drug Index, which includes leading companies like WuXi Biologics, Innovent Biologics, and BeiGene, with nearly 90% weight in biopharmaceuticals and chemical drugs [2] - The ETF allows T+0 trading and has established off-market connection funds for investors to maintain interest in the high-volatility Hong Kong innovative drug sector [2]

Group 1 - The Hong Kong stock market saw a collective rise in pharmaceutical outsourcing concept stocks, with WuXi AppTec increasing by 5%, and other companies like Zai Lab, WuXi Biologics, and Vyaire Biopharma rising over 4% [1] - WuXi AppTec reported Q3 2025 revenue of 12.057 billion, a year-on-year increase of 15.26%, and a net profit attributable to shareholders of 3.515 billion, up 53.27% [1] - For the first three quarters, WuXi AppTec's revenue reached 32.857 billion, reflecting an 18.61% year-on-year growth, while net profit attributable to shareholders was 12.076 billion, marking an 84.84% increase [1] Group 2 - WuXi AppTec's full subsidiary plans to transfer 100% equity of two companies for a base price of 2.8 billion to Shanghai Shihe Rong Enterprise Management Consulting Co., Ltd. and Shanghai Shihe Mu Enterprise Management Consulting Co., Ltd. [1] - The stock performance of various companies in the sector includes WuXi AppTec with a year-to-date increase of 112.32%, Zai Lab at 105.43%, WuXi Biologics at 115.49%, and Vyaire Biopharma at 194.19% [2] - Other notable stock performances include Tigermed with a 40.97% increase and Kanglong Chemical with an 85.29% rise year-to-date [2]

Core Insights - The Hong Kong Medical ETF (159366) and the CSI Hong Kong Stock Connect Medical Theme Index (932069) have shown strong performance, with the index rising by 2.35% and the ETF by 2.42% on the opening day [1] - WuXi AppTec (药明康德) reported significant growth in its Q3 2025 financial results, with a revenue of 12.057 billion yuan, a year-on-year increase of 15.26%, and a net profit of 3.515 billion yuan, reflecting a 53.27% increase [3] - The strong performance of WuXi AppTec is attributed to its core business growth, particularly in the chemical segment, which saw a revenue increase of 29.3% year-on-year [3] Company Performance - WuXi AppTec's Q3 revenue was 12.057 billion yuan, with a net profit of 3.515 billion yuan, and a non-recurring gain of 3.223 billion yuan from the sale of equity in WuXi XDC Cayman Inc. [3] - The chemical business is the main growth driver, with TIDES (peptides and oligonucleotides) revenue reaching 7.84 billion yuan, a remarkable increase of 121.1% year-on-year [3] - The company's core strategy in CRDMO is yielding high growth, with a 17.1% increase in orders in the TIDES sector [3] Industry Trends - The overseas CXO industry is experiencing a recovery, with an increase in BD transactions and M&A activities, indicating a positive trend in global client demand [4] - Leading CXO companies with a global client base and advanced manufacturing capabilities are expected to benefit from this recovery [5] - The top ten weighted stocks in the CSI Hong Kong Stock Connect Medical Theme Index account for 62.95% of the index, highlighting the concentration of investment in key players like WuXi AppTec and JD Health [5]

Group 1 - The Hong Kong stock market opened higher on October 27, with technology and semiconductor stocks showing strength [1] - The Hong Kong Stock Connect Technology ETF (513860) rose by 1.96% with a trading volume exceeding 30 million yuan, indicating strong investor interest [1] - Notable performers among the ETF's constituent stocks included Hongteng Precision, which increased by over 7%, and WuXi AppTec and WuXi Biologics, both rising by over 6% [1] Group 2 - According to Xinda Securities, the derivatives market is showing positive signals despite a reduction in positions, with the basis of the Shanghai 50 index futures turning to a premium, indicating improved sentiment in blue-chip stocks [2] - Huatai Securities noted that southbound capital has accumulated inflows exceeding 500 billion HKD since the second half of the year, suggesting a balanced risk outlook in the market [2] - The current high prosperity in sectors such as metals, materials, and energy, along with technology, contrasts with the recent bottoming or upward revision signs in consumer sectors and high-dividend stocks [2]